目的逍遥解郁方治疗脑卒中后抑郁的疗效及对血清细胞因子、P13K/Akt信号通路蛋白的影响。方法选取2018年3月—2019年6月期间就诊于河北省沧州中西医结合医院脑病科的150例脑卒中后抑郁患者,采用随机双盲安慰剂对照法,将其随机分为安慰...目的逍遥解郁方治疗脑卒中后抑郁的疗效及对血清细胞因子、P13K/Akt信号通路蛋白的影响。方法选取2018年3月—2019年6月期间就诊于河北省沧州中西医结合医院脑病科的150例脑卒中后抑郁患者,采用随机双盲安慰剂对照法,将其随机分为安慰剂对照组、盐酸氟西汀对照组、逍遥解郁方治疗组3组,每组各50例。3组患者均给予脑卒中的基础治疗,在此基础上,安慰剂对照组给予安慰剂胶囊+安慰剂汤剂;盐酸氟西汀对照组患者给予盐酸氟西汀口服+安慰剂汤剂;逍遥解郁方治疗组给予盐酸氟西汀+逍遥解郁方。3组患者均连续治疗8周,并随访至12周。分别于治疗前、治疗4周末、治疗8周末以及随访第12周末,检测汉密尔顿抑郁量表(Hamilton Depression Scale,HAMD)、美国国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)、日常生活能力(Activity of Daily Living Scale,ADL)量表Barthel指数、中医证候积分,检测脑脊液蛋白[BCL2-Associated X蛋白质(BCL2 associated X protein,Bax)、B淋巴瘤基因(B-cell lymphoma,Bcl)、磷酸化丝氨酸/苏氨酸蛋白激酶(Phosphorylated serine/threonine protein kinase,pAkt)、磷脂酰肌醇3激酶(Phosphoinositide 3-kinase,PI3K)]水平、相关血清细胞因子[肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)、超敏C反应蛋白(Hypersensitive c-reactive protein,hs-CRP)、同型半胱氨酸(Homocysteine,Hcy)]水平,并进行临床疗效评价。结果治疗后安慰剂对照组、盐酸氟西汀对照组、逍遥解郁方治疗组总有效率分别为70.45%、81.40%、93.18%,盐酸氟西汀对照组、逍遥解郁方治疗组与安慰剂对照组比较,差异有统计学意义(P<0.05);逍遥解郁方治疗组与盐酸氟西汀对照组比较,差异有统计学意义(P<0.05)。治疗4、8周、随访至第12周后逍遥解郁方治疗组HAMD、NIHSS评分、中医证候积分均低于安慰剂对照组和盐酸氟西汀对照组,差异有统计学意义(展开更多
Objective： The objective of this study is to evaluate the clinical efficacy of Xiaoyao Jieyu prescription （XJP） in the treatment of persistent postural-perceptual dizziness （PPPD）. Methods： A total of 33 ...Objective： The objective of this study is to evaluate the clinical efficacy of Xiaoyao Jieyu prescription （XJP） in the treatment of persistent postural-perceptual dizziness （PPPD）. Methods： A total of 33 PPPD patients were randomly divided into test group and control group. Two groups of patients were given psychological treatment. The test group was given XJP and the control group was given escitalopram. The course of treatment was 12 weeks. Before and after 4 weeks and 8 weeks and 12 weeks, the dizziness handicap inventory （DHI）, Hamilton anxiety scale （HAMA） and Hamilton Depression scale （HAMD） were used to evaluate the treatment effect. Results： The total scores of HAMA, HAMD, DHI and the respective factor scores of DHI significantly decreased in both groups after 4 weeks of treatment compared with those before the treatment （P 〈 0.01）. The DHI scores and the score of function, physiology at 8-week, 12-week, as well as the HAMA and HAMD scores at 4-week, 8-week, 12-week in the test group were significantly lower than those in the control group （P 〈 0.05）. The incidence of adverse reactions in the test group was significantly lower than the control group （P 〈 0.05）. Conclusion： XJP can improve the clinical symptoms of patients with PPPD. It can both improve the physical and functional symptoms of PPPD and reduce anxiety and depression. In the course of treatment, the adverse reaction of the prescription is less and mild. It has the advantages of high efficiency, safety, low price and easy access to materials.展开更多
文摘目的逍遥解郁方治疗脑卒中后抑郁的疗效及对血清细胞因子、P13K/Akt信号通路蛋白的影响。方法选取2018年3月—2019年6月期间就诊于河北省沧州中西医结合医院脑病科的150例脑卒中后抑郁患者,采用随机双盲安慰剂对照法,将其随机分为安慰剂对照组、盐酸氟西汀对照组、逍遥解郁方治疗组3组,每组各50例。3组患者均给予脑卒中的基础治疗,在此基础上,安慰剂对照组给予安慰剂胶囊+安慰剂汤剂;盐酸氟西汀对照组患者给予盐酸氟西汀口服+安慰剂汤剂;逍遥解郁方治疗组给予盐酸氟西汀+逍遥解郁方。3组患者均连续治疗8周,并随访至12周。分别于治疗前、治疗4周末、治疗8周末以及随访第12周末,检测汉密尔顿抑郁量表(Hamilton Depression Scale,HAMD)、美国国立卫生研究院卒中量表(National Institute of Health stroke scale,NIHSS)、日常生活能力(Activity of Daily Living Scale,ADL)量表Barthel指数、中医证候积分,检测脑脊液蛋白[BCL2-Associated X蛋白质(BCL2 associated X protein,Bax)、B淋巴瘤基因(B-cell lymphoma,Bcl)、磷酸化丝氨酸/苏氨酸蛋白激酶(Phosphorylated serine/threonine protein kinase,pAkt)、磷脂酰肌醇3激酶(Phosphoinositide 3-kinase,PI3K)]水平、相关血清细胞因子[肿瘤坏死因子-α(Tumor necrosis factor-α,TNF-α)、超敏C反应蛋白(Hypersensitive c-reactive protein,hs-CRP)、同型半胱氨酸(Homocysteine,Hcy)]水平,并进行临床疗效评价。结果治疗后安慰剂对照组、盐酸氟西汀对照组、逍遥解郁方治疗组总有效率分别为70.45%、81.40%、93.18%,盐酸氟西汀对照组、逍遥解郁方治疗组与安慰剂对照组比较,差异有统计学意义(P<0.05);逍遥解郁方治疗组与盐酸氟西汀对照组比较,差异有统计学意义(P<0.05)。治疗4、8周、随访至第12周后逍遥解郁方治疗组HAMD、NIHSS评分、中医证候积分均低于安慰剂对照组和盐酸氟西汀对照组,差异有统计学意义(
文摘Objective： The objective of this study is to evaluate the clinical efficacy of Xiaoyao Jieyu prescription （XJP） in the treatment of persistent postural-perceptual dizziness （PPPD）. Methods： A total of 33 PPPD patients were randomly divided into test group and control group. Two groups of patients were given psychological treatment. The test group was given XJP and the control group was given escitalopram. The course of treatment was 12 weeks. Before and after 4 weeks and 8 weeks and 12 weeks, the dizziness handicap inventory （DHI）, Hamilton anxiety scale （HAMA） and Hamilton Depression scale （HAMD） were used to evaluate the treatment effect. Results： The total scores of HAMA, HAMD, DHI and the respective factor scores of DHI significantly decreased in both groups after 4 weeks of treatment compared with those before the treatment （P 〈 0.01）. The DHI scores and the score of function, physiology at 8-week, 12-week, as well as the HAMA and HAMD scores at 4-week, 8-week, 12-week in the test group were significantly lower than those in the control group （P 〈 0.05）. The incidence of adverse reactions in the test group was significantly lower than the control group （P 〈 0.05）. Conclusion： XJP can improve the clinical symptoms of patients with PPPD. It can both improve the physical and functional symptoms of PPPD and reduce anxiety and depression. In the course of treatment, the adverse reaction of the prescription is less and mild. It has the advantages of high efficiency, safety, low price and easy access to materials.
